Dr Reddys Laboratories (RDY) Operating Expenses (2009 - 2023)

Dr Reddys Laboratories' Operating Expenses history runs 15 years deep, the most recent figure standing at $292.0 million for Q2 2023.

• On a quarterly basis, Operating Expenses changed N/A year-over-year to $292.0 million in Q2 2023; TTM through Mar 2026 was $292.0 million, a 48.32% decrease from a year earlier, with the FY2026 full-year figure at $1.4 billion, down 2.74% from the prior year.
• Operating Expenses rose to $292.0 million in Q2 2023 per RDY's latest filing, from $273.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $292.0 million in Q2 2023 and bottomed at $228.0 million in Q1 2020.
• The 5-year median for Operating Expenses is $258.5 million (2020), against an average of $257.8 million.
• Across the five-year window, Operating Expenses gained 1.69% in 2020 and rose 15.79% in 2021, its largest moves.
• Year by year, Operating Expenses stood at $233.0 million in 2019, then advanced by 8.58% to $253.0 million in 2020, then increased by 8.7% to $275.0 million in 2021, then increased by 3.27% to $284.0 million in 2022, then advanced by 2.82% to $292.0 million in 2023.
• Per Business Quant, the three latest RDY Operating Expenses figures stand at $292.0 million (Q2 2023), $273.0 million (Q1 2023), and $284.0 million (Q4 2022).